- •Foreword
- •Preface
- •Contents
- •1: Facial Anatomy
- •1.1 Introduction
- •1.2 Facial Skeleton
- •1.5 Retaining Ligaments
- •1.6 Mimetic Muscles
- •1.7 Deep Plane Including the Deep Fat Compartments
- •1.8 Facial Nerve
- •1.9 Sensory Nerves
- •1.10 Arteries of the Face
- •References
- •2: Facial Proportions
- •2.1 Introduction
- •2.2 Surface Markings
- •2.3 Proportions
- •2.4 The Golden Ratio
- •2.5 Planes and Angles
- •2.6 Conclusions
- •References
- •3.1 Introduction
- •3.2 Details of Zones
- •3.2.1 Zone 1
- •3.2.2 Zone 2
- •3.2.3 Zone 3
- •3.2.4 Zone 4
- •3.2.5 Zone 5
- •3.2.6 Zone 6
- •3.2.7 Zone 7
- •3.3 Conclusions
- •References
- •4: Muscles Used in Facial Expression
- •4.1 Introduction
- •4.2 Discussion
- •References
- •5.1 Introduction
- •5.2 Studies and Technique
- •5.3 Results
- •5.4 Discussion
- •5.4.1 SMAS and SMAFS: Concept and Variations
- •5.4.1.1 Sleep Lines
- •5.4.1.2 Membranous SMAFS
- •5.4.1.3 Fatty SMAFS
- •5.4.1.4 Flaccid SMAFS
- •5.4.1.5 Mixed SMAFS
- •5.4.1.7 Fleshy SMAFS
- •5.4.1.8 Fibrous SMAFS
- •5.4.1.9 SMAFS Sleep Lines Correction
- •5.5 Conclusions
- •References
- •6.1 Introduction
- •6.2 Surgical Facility
- •6.3 Ancillary Personnel
- •6.4 Preoperative Evaluation
- •6.4.1 Preoperative Risk Assessment
- •6.4.3 Cardiac Disease
- •6.4.4 Obesity
- •6.4.5 Hypertension
- •6.4.6 Diabetes Mellitus
- •6.4.7 Pulmonary Disease
- •6.4.8 Obstructive Sleep Apnea
- •6.4.9 Malignant Hyperthermia Susceptibility
- •6.5 Selections and Delivery of Anesthesia
- •6.5.1 Local Anesthesia
- •6.5.3 Regional Anesthesia
- •6.5.4 General Anesthesia
- •6.5.5 Preoperative Preparation
- •6.5.6 Perioperative Monitoring
- •6.5.7 Fluid Replacement
- •6.5.8 Recovery and Discharge
- •References
- •Recommended Reading
- •7.1 Introduction
- •7.3 Other Considerations
- •7.4 Assessing Level of Sedation
- •7.5 Agents Used in Sedation
- •7.5.1 Propofol
- •7.5.2 Benzodiazepines
- •7.5.3 Clonidine and Dexmedetomidine
- •7.5.4 Ketamine
- •7.5.5 Opioids
- •7.5.6 Acetaminophen
- •7.5.8 Other Agents
- •7.6 Devices Used in the Delivery of Sedation
- •7.7 Postoperative Nausea and Vomiting (PONV)
- •7.7.1 Risk Factors
- •7.8 Techniques of Sedation
- •7.9 Conclusions
- •References
- •8: Preoperative and Postoperative Plan
- •8.1 Plan for Facelift Surgery
- •8.2 Facelift Preoperative Instructions
- •References
- •9: Facial Imaging
- •9.1 Introduction
- •9.2 The Camera
- •Practical Tips
- •9.3 Resolution
- •Practical Tips on Resolution
- •9.4 Lighting
- •Practical Tips
- •9.5 Background
- •Practical Tips
- •9.6 Advertising and Ethics
- •9.7 Before and After Photos
- •9.8 Consent
- •Practical Tips for Consent for Photography
- •9.9 Special Problems with Consent
- •9.10 Radiology
- •9.10.1 Computed Tomography (CT)
- •9.10.2 Magnetic Resonance Imaging (MRI)
- •10.1 Introduction
- •10.2 Skin Aging
- •10.3 Techniques
- •10.3.1 Skin Care Program
- •10.3.1.1 Tretinoin
- •10.3.1.2 Skin Cleansers
- •10.3.1.3 Sun Protection
- •10.3.1.4 Light Chemical Peel or “Friendly Peel”
- •10.3.1.5 Microdermabrasion
- •10.3.1.6 Carboxytherapy
- •10.4 Complications
- •10.5 Discussion
- •10.6 Conclusions
- •References
- •11: What Is Human Beauty?
- •11.1 Introduction
- •11.2 Beauty
- •11.2.1 What Is Human Beauty? What Do the Books Say? Dictionaries? Philosophers?
- •11.2.2 Konrad Lorenz’s Theory
- •11.3 Conclusion
- •11.4 Summary
- •12: Body Dysmorphic Disorder
- •12.2 Symptoms
- •12.3 Consequences of BDD
- •12.4 Associated Disorders
- •12.5 Treatment
- •12.6 Discussion
- •12.7 Conclusions
- •References
- •13: Hair Transplantation
- •13.1 Introduction
- •13.3 Modern Hair Transplantation and Terminology
- •13.4 Nonsurgical Treatment Options
- •13.4.1 Medications
- •13.5 Nonmedical Treatments
- •13.6 Preoperative Consultation
- •13.7 Female Considerations
- •13.8 Preoperative Instructions
- •13.9 Surgical Planning
- •13.9.1 Men with MPB
- •13.9.2 The Crown
- •13.9.3 Females
- •13.9.4 Selection of Donor Area Site and Size
- •13.9.5 Estimating Size of Donor Strip
- •13.10 Anesthesia
- •13.11 Removal of Donor Strip
- •13.12 Follicular Unit Extraction
- •13.12.1 Indications for FUE
- •13.12.2 Advantages of FUE
- •13.12.3 Disadvantages of FUE
- •13.13 Graft Preparation
- •13.14 Recipient Site Creation
- •13.15 Graft Orientation: CAG or SAG
- •13.16 Instruments (Table 13.3)
- •13.17 Re-creating a Natural Hairline
- •13.18 Planting Recipient Grafts
- •13.19 The Vertex Region
- •13.20 Postoperative Care
- •13.21 Complications
- •13.21.1 Surgical Complications/Side Effects
- •13.21.2 Cosmetic/Esthetic Complications
- •13.22 Examples of Applications for Hair Transplants
- •13.22.1 Male Pattern Baldness
- •13.22.2 Female Pattern Hair Loss
- •13.22.3 Transplants After Rhytidectomy
- •13.22.4 Transplants After Burns
- •13.23 Non-scalp Areas
- •13.24 Transgendered Patients
- •13.25 Conclusions
- •References
- •14: Ablative Laser Facial Resurfacing
- •14.1 Introduction
- •14.2 Technique
- •14.2.1 Preoperative Preparation
- •14.2.2 Carbon Dioxide Laser
- •14.2.3 Erbium Laser
- •14.2.4 Postoperative Care
- •14.3 Complications
- •14.4 Discussion
- •14.5 Conclusions
- •References
- •15: Photorejuvenation
- •15.1 Introduction
- •15.2 Technique
- •15.3 Complications
- •15.4 Discussion
- •15.5 Conclusions
- •References
- •16.1 Introduction
- •16.2 Skin Anatomy
- •16.3 Technique
- •16.3.1 Patient Selection
- •16.3.2 Pretreatment
- •16.3.3 Technique
- •16.4 Alpha Hydroxy Acids
- •16.5 Salicylic Acid
- •16.6 Jessner’s Peel
- •16.6.1 Medium Depth Peels
- •16.7 Trichloroacetic Acid
- •16.8 Adjunctive Measures
- •16.9 Postoperative Care
- •16.10 Complications
- •16.11 Discussion
- •16.12 Conclusions
- •References
- •17: Deep Phenol Chemical Peels
- •17.1 Introduction
- •17.2 Patient Selection
- •17.3 Technique
- •17.4 Complications
- •17.5 Conclusions
- •References
- •18: Chemical Blepharoplasty
- •18.1 Introduction
- •18.2 Skin Preparation
- •18.3 Skin Evaluation and Chemical Agent Selection
- •18.4 Anesthesia and Sedation
- •18.5 Details of the Procedure
- •18.6 The Postoperative Period
- •18.7 Complications
- •18.7.1 Ectropion
- •18.7.4 Web Formation
- •18.7.5 Eyelid Skin Infection
- •18.8 Discussion
- •18.9 Conclusion
- •References
- •19: Facial Implants
- •19.1 Introduction
- •19.2 Technique
- •19.2.1 Midface Implants
- •19.2.2 Mandibular Implants
- •19.3 Complications
- •19.4 Discussion
- •19.5 Conclusions
- •References
- •20: Injectable Facial Fillers
- •20.1 Introduction
- •20.2 Historical Background
- •20.3 Available Facial Fillers
- •20.3.1 Autologous Fat
- •20.3.2 Collagen
- •20.3.3 Hyaluronic Acids (HAs)
- •20.3.4 Synthetic Polymers
- •20.4 Technical Considerations
- •20.5 Injection Techniques
- •20.6 Post-procedural Considerations
- •20.7 Facial Filler Complications
- •20.8 Conclusions
- •References
- •Recommended Reading
- •21: Botulinum Toxin for Facial Rejuvenation
- •21.1 Introduction
- •21.2 History
- •21.3 Chemical Overview
- •21.5 Onset and Duration of Paralysis
- •21.10 Locations of Treatment
- •21.10.1 Upper Face
- •21.10.2 Midface
- •21.10.3 Lower Face
- •21.11 New Frontiers for Botulinum Toxin in Facial Rejuvenation
- •21.12 Contraindications
- •21.13 Avoidance of Potential Pitfalls
- •21.15 Conclusions
- •References
- •22: History of Fat Transfer
- •22.1 Introduction
- •22.2 History
- •References
- •23.1 Introduction
- •23.2 Relevant Anatomy and Pathophysiology
- •23.3 Clinical Applications
- •23.3.1 Harvesting the Fat
- •23.3.2 Preparation
- •23.4 Applications and Injection Techniques
- •23.4.1 Injection Methods
- •23.5 Complications
- •References
- •24.1 Introduction
- •24.2 Patient Assessment
- •24.4 Anatomy
- •24.5 Liposuction
- •24.6 Tumescent Anesthesia
- •24.7 Liposuction Technique
- •24.8 Summary of Critical Points for Successful Liposuction
- •24.9 Chin Implantation
- •24.10 Submentoplasty
- •24.10.1 Submentoplasty Technique
- •24.11 Dealing with the Visible Submandibular Gland
- •24.12 Complications
- •24.12.1 Over-resection of Fat
- •24.12.2 Sialocele
- •24.12.3 Nerve Injury
- •24.12.4 Seroma
- •24.12.5 Skin Redundancy
- •24.12.6 Chronic Pain
- •24.12.8 Infection
- •24.12.9 Bleeding and Hematomas
- •24.12.10 Skin Slough
- •24.13 Conclusions
- •References
- •Submental Liposuction
- •26: Vaser UAL for the Heavy Face
- •26.1 Introduction
- •26.2 Technologies
- •26.3 Technique
- •26.4 Complications
- •27: Suture Facelift Techniques
- •27.1 Introduction
- •27.2 Concept
- •27.3 Patient Selection
- •27.4 Suture Types and Materials
- •27.4.1 Barbed Sutures
- •27.4.1.2 Anchored Bidirectional Barbed Sutures
- •27.4.1.3 Unidirectional Barbed Sutures
- •27.4.2 Non-barbed Sutures
- •27.4.2.1 Nonabsorbable Non-barbed Sutures
- •27.4.2.2 Absorbable Non-barbed Sutures
- •Upper Face
- •Midface
- •Lower Face
- •Neck
- •27.4.3 Coned Sutures
- •27.4.3.1 Midface
- •27.4.3.2 Neck
- •27.5 Postoperative Care
- •27.6 Complications
- •27.7 Conclusions
- •References
- •28: Bio-Lifting and Bio-Resurfacing
- •28.1 Introduction
- •28.2 Patient Desires
- •28.3 Aging of the Face
- •28.4 T3 Bioresurfacing
- •28.4.2 Young-Peel Method
- •28.4.2.2 Transdermal Introduction of Substances (Trans Peel)
- •28.4.3 Photodynamic Treatment
- •28.6 Biolifting
- •28.6.1 Method
- •28.6.1.2 Middle Layer
- •28.6.1.3 Deep Layer
- •28.6.1.4 Threads of Support
- •28.7 Endo Light Lift
- •28.8 Biodermogenesi™
- •28.9 Bio-Lifting: Protocol of Treatment
- •28.10 Conclusions
- •References
- •29: Standard Facelifting
- •29.1 Introduction
- •29.2 Technique
- •29.3 Postoperative Care
- •29.4 Complications
- •29.4.1 Hematoma
- •29.4.2 Nerve Injury
- •29.4.3 Infection
- •29.4.4 Skin Flap Necrosis
- •29.4.5 Hypertrophic Scarring
- •29.4.7 Parotid Gland Pseudocyst
- •29.5 Discussion
- •29.6 Conclusions
- •References
- •30.1 Introduction
- •30.4 Role of the Retaining Ligaments in Aging Face
- •30.5 Role of the Retaining Ligaments on Facelift
- •30.7 Presurgical Planning of Facelift
- •30.8 Facelift Procedure with Release and Suspension of the Retaining Ligaments and SMAS
- •30.8.1 Design of Skin Incision
- •30.8.2 Dissection
- •30.8.3 Liposuction
- •30.8.4 Treatment of Crow’s Feet and Sagging Lower Eyelid
- •30.8.5 Suspension
- •30.9 Clinical Cases
- •30.9.1 Case 1
- •30.9.2 Case 2
- •References
- •31.1 Introduction
- •31.2 Consultation
- •31.3.2 Photography
- •31.3.4 Preoperative Preparation on the Operating Table
- •31.3.5 Anesthesia: Intravenous Sedation
- •31.3.6 Nerve Mapping
- •31.3.8 Instrumentation
- •31.4 Procedure
- •31.5 The SMAS
- •31.6 Dressings
- •31.7 Results
- •References
- •32.1 Introduction
- •32.2 Technique
- •32.3 Complications
- •32.4 Discussion
- •32.5 Conclusions
- •References
- •33.1 Introduction
- •33.3.1 Marking
- •33.3.2 Anesthesia
- •33.4.1 Dressings
- •33.6 Disadvantages
- •References
- •34.1 Introduction
- •34.2 Strategy and Selection of SMAS Flap
- •34.3 SMAS Flap Study
- •34.4 Discussion
- •34.5 Conclusions
- •References
- •35.1 Introduction
- •35.2 Anatomic Considerations
- •35.2.1 The Facial Nerve
- •35.2.2 The SMAS Layer
- •35.3 Indications
- •35.4 Technique
- •35.5 Discussion
- •35.6 Complications
- •35.6.1 Hematoma
- •35.6.2 Nerve Injury
- •35.7 Conclusions
- •References
- •Recommended Reading
- •36.1 Introduction
- •36.2 Surgical and Functional Anatomy of the Face
- •36.2.1 Parotidomasseteric Fascia
- •36.2.2 Temporal Fascia
- •36.2.3 Deep Cervical Fascia
- •36.2.4 Malar: Buccal Fat Pad
- •36.2.5 Facial Mimetic Muscles
- •36.2.6 Facial Nerve
- •36.2.7 Retaining Ligaments
- •36.3 Anatomicohistologic Study of the Retaining Ligaments of the Face
- •36.3.1 Zygomatic Cutaneous Ligament (McGregor’s Patch)
- •36.3.2 Preauricular Parotid Cutaneous Ligament
- •36.3.3 Parotidomasseteric Cutaneous Ligament
- •36.3.4 Platysma Cutaneous Ligament
- •36.3.5 Mandibular Ligament
- •36.4 Aging Changes in the Face
- •36.5 Facelift and Historical Development of Retaining Ligaments of the Face
- •36.6 Retaining Ligament Correction and SMAS Plication in Facelift
- •36.6.1 Preparations for Surgery and Skin Marking
- •36.6.2 Surgical Technique
- •36.7 Postoperative Care and Complications
- •References
- •37.1 Introduction
- •37.2 Technique
- •37.3 Conclusions
- •References
- •38.1 Introduction
- •38.2 Preoperative Evaluation
- •38.3 Preoperative Markings
- •38.4 Anesthesia
- •38.5 Deep Plane Technique
- •38.6 Postoperative Care
- •38.7 Complications
- •38.8 Discussion
- •Recommended Reading
- •39: Subperiosteal Face-Lift
- •39.1 Introduction
- •39.2 Technique
- •39.2.1 Preoperative Evaluation
- •39.2.2 Surgical Technique
- •39.3 Complications
- •39.4 Discussion
- •39.5 Conclusions
- •References
- •40.1 Introduction
- •40.2 Limited Flap Rhytidectomy Procedures
- •40.3 Extended Flap Rhytidectomy Procedures
- •40.4 Deep-Plane Rhytidectomy
- •40.5 Adjuvant Procedures
- •References
- •41.1 Introduction
- •41.2 Pathomechanics
- •41.3 Preoperative Evaluation
- •41.3.1 Rhytidectomy in the Postbariatric Patient
- •41.4 Postoperative Care and Complications
- •41.5 Conclusions
- •References
- •42: Complications of Facelift Surgery
- •42.1 Introduction
- •42.2 Complications
- •42.2.1 Asymmetry
- •42.2.2 Bleeding
- •42.2.3 Dehiscence
- •42.2.5 Ear Deformities
- •42.2.6 Edema
- •42.2.7 Hair Loss
- •42.2.8 Hematoma
- •42.2.9 Infection
- •42.2.10 Irregularities
- •42.2.11 Necrosis
- •42.2.12 Neurological
- •42.2.13 Pain
- •42.2.14 Pigmentation Changes
- •42.2.15 Salivary Fistula
- •42.2.16 Scar
- •42.2.17 Seroma
- •References
- •43.1 Introduction
- •43.2 Historical Review
- •43.3 Anatomic Guidelines
- •43.4 The Eyebrow and Forehead as an Aesthetic Unit
- •43.5 Position of the Eyebrows
- •43.6 General Indications
- •43.7.1 Frontal Ptosis Degree
- •43.7.2 Depth of the Skin Furrows
- •43.7.3 Asymmetries
- •43.7.4 Frontal Redundant Skin
- •43.8 What Fixing Approaches and Techniques Do We Use?
- •43.8.1 Coronal
- •43.8.2 Pretrichial/Trichial
- •43.8.3 “Half Frontal”
- •43.8.4 Direct Eyebrow Lift
- •43.8.5 Endoscopic
- •43.9 Complications
- •43.10 Discussion
- •43.11 Conclusions
- •References
- •44: Endoscopic Forehead Lift
- •44.1 Forehead Aging Process
- •44.2 Indications
- •44.3 Alternative Methods
- •44.4 Anatomy
- •44.5 Endoscopic Forehead Lift Surgery: Rationale
- •44.6 Technique
- •44.6.1 Instruments
- •44.6.2 Anesthesia
- •44.6.3 Delimitation of the Working Areas
- •44.6.4 Skin Incisions
- •44.6.5 Subaponeurotic Supraperiosteal Dissection
- •44.6.6 Subperiosteal Dissection
- •44.6.7 Interfascial Dissection
- •44.6.8 Communication Between the Two Pockets
- •44.6.9 Endoscope Placement and Use
- •44.6.10 Periosteal and Muscular Sectioning
- •44.6.11 Fixation Suture Placement
- •44.6.12 Closure
- •44.6.13 Postoperative Follow-Up
- •44.7 Complications
- •44.8 Discussion
- •References
- •45.1 Introduction
- •45.2 History
- •45.3 Forehead Anatomy
- •45.5 Nonsurgical Techniques in Forehead Rejuvenation
- •45.6.1 Autogenous Fat Injection
- •45.6.2 Moisturizing Graft
- •45.6.3 Open Frontal Lift
- •45.6.4 Periorbital Approach
- •45.6.6 Forehead Endoscopic Rejuvenation
- •45.7 Complications
- •45.8 Conclusions
- •References
- •46.1 Introduction
- •46.2 Patient Marking
- •46.3 Surgical Procedure
- •46.4 Complications
- •46.5 Discussion
- •46.6 Conclusions
- •References
- •47: Endobrow Lift
- •47.1 Introduction
- •47.2 Anatomy
- •47.3 Endobrow Lift
- •47.3.1 Objectives of a Brow Lift
- •47.3.2 Preoperative Counseling
- •47.3.3 Learning Curve
- •47.3.5 Surgical and Nonsurgical Treatments of Forehead Rejuvenation
- •47.3.6 Direct Operations to the Brow
- •47.3.7 Endoscopic Brow Lift
- •47.3.8 Risks
- •47.4 Variations of Forehead and Brow Lift
- •47.5 Transpalpebral Corrugator Resection
- •47.6 Coronal Incision
- •47.7 Fat Grafting
- •47.8 Suspension and Suture Techniques
- •47.8.1 Thread Lift Guide
- •47.8.2 Thread Lift Risks
- •47.9 Botox (Chemodenervation with Botulinum Toxin)
- •47.10 Endobrow
- •47.10.1 Screw Placement
- •47.10.2 Possible Complications
- •References
- •48: Minimally Invasive Midface Lift
- •48.1 Introduction
- •48.2 Surgical Goals
- •48.3 Indications and Contraindications
- •48.4 Surgical Technique
- •48.4.1 Preoperative Markings
- •48.4.2 Anesthesia
- •48.4.5 Anchoring the Suture to the Deep Temporalis Fascia
- •48.5 Complications
- •48.6 Conclusions
- •Recommended Reading
- •49: Upper Eyelid Blepharoplasty
- •49.1 Introduction
- •49.2 Periorbital Aging
- •49.3 Anatomic Considerations
- •49.4 Musculature
- •49.5 Orbital Septum
- •49.6 Levator Palpebrae Superioris
- •49.7 Orbital Fat
- •49.8 Preoperative Evaluation
- •49.9 Ocular Assessment
- •49.10 Operative Procedure
- •49.11 Upper Eyelid Blepharoplasty Approach
- •49.12 Preparation
- •49.13 Postoperative Care
- •49.14 Complementary Treatments
- •49.14.1 Restoration of Infrabrow and Lateral Brow Volume
- •49.14.2 Injectable Fillers
- •49.14.3 Structural Fat Grafting of the Infrabrow Region
- •49.15 Complications
- •49.15.1 Hematomas
- •49.15.2 Blindness
- •49.15.3 Epiphora
- •49.15.4 Suture Line Complications
- •49.15.5 Wound Healing Complications
- •49.15.6 Ocular Injury
- •49.15.7 Contour Irregularities
- •References
- •50: Lower Eyelid Blepharoplasty
- •50.1 Introduction
- •50.2 Periorbital Aging
- •50.3 Anatomic Considerations
- •50.3.1 Lamellae
- •50.3.2 Musculature
- •50.3.3 Orbital Fat
- •50.3.4 Infraorbital and Midface Anatomy
- •50.4 Preoperative Evaluation
- •50.4.1 Ocular Assessment
- •50.4.3 Assessment of Tear Trough or Nasojugal Deformity
- •50.5 Operative Procedure
- •50.5.1 Technique
- •50.5.1.1 Transconjunctival Approach
- •Preparation
- •Postoperative Care
- •50.5.1.2 Skin–Muscle Flap Approach
- •Preparation
- •Incision
- •Fat Removal
- •Closure
- •Postoperative Care
- •50.6 Complementary Treatments with Restoration of Infraorbital Volume
- •50.6.1 Injectable Fillers
- •50.6.2 Orbital Fat Repositioning
- •50.6.3 Suborbicularis Oculi Fat Lift
- •50.7 Structural Fat Grafting of the Infraorbital Region
- •50.8 Complications
- •50.8.1 Ectropion
- •50.8.2 Hematomas
- •50.8.3 Blindness
- •50.8.4 Epiphora
- •50.8.5 Suture Line Complications
- •50.8.6 Wound Healing Complications
- •50.8.7 Skin Discoloration
- •50.8.8 Ocular Injury
- •50.8.9 Contour Irregularities
- •References
- •51: Upper Blepharoplasty of the Asian Eyelid
- •51.1 Introduction
- •51.2 Instrument List
- •51.3 Operative Technique
- •51.4 Postoperative Care
- •Reference
- •52: Medial and Lateral Epicanthoplasty
- •52.1 Introduction
- •52.3 Technique
- •52.3.1 Medial Epicanthoplasty
- •52.3.1.1 Elliptical excision: Von Ammon, Arlt, Hiraga, and Watanabe methods
- •52.3.1.2 Z-Plasty Method
- •52.3.2 Lateral Epicanthoplasty
- •52.4 Complications
- •52.5 Conclusions
- •References
- •53.1 Introduction
- •53.2 Hyaluronic Acid Gel Filler
- •53.3 Patient Marking and Preparation
- •53.4 The Injection
- •53.5 Complications
- •53.6 Discussion
- •53.7 Conclusions
- •References
- •54: Combined Technique in Otoplasty
- •54.1 Introduction
- •54.2 Technique
- •54.3 Complications
- •54.4 Discussion
- •54.5 Conclusions
- •References
- •55: Rhinoplasty
- •55.1 Introduction
- •55.2 Types of Nasal Deformity
- •55.3 Preoperative Analysis
- •55.4 Surgical Techniques
- •55.4.1 Incisions in Rhinoplasty
- •55.4.2 Osteotomies in Rhinoplasty
- •55.5 Complications
- •55.5.1 Intrasurgical Complications
- •55.5.2 Immediate Postoperative Complications
- •55.5.3 Early Postoperative Complications
- •55.5.4 Late Postoperative Complications
- •55.6 Conclusions
- •References
- •56.1 Introduction
- •56.2 Biochemistry
- •56.3 Storage
- •56.4 Mechanism of Action
- •56.5 Duration of Action
- •56.6 Clinical Uses
- •56.6.1 FDA-Approved Uses
- •56.6.2 Aesthetic Off-Label Uses
- •56.8 Nonsurgical Rhinoplasty
- •56.8.1 Initial Consult
- •56.8.2 Physical Examination
- •56.8.3 Nasal Anatomy
- •56.8.4 Anesthesia and Prophylaxis
- •56.8.5 Needles
- •56.8.6 Injection Technique
- •56.8.7 Dosage
- •56.8.8 Postinjection Care
- •56.8.9 Patient Satisfaction
- •56.9.1 Asian
- •56.9.2 African-American
- •56.9.3 Hispanic
- •56.9.4 Arabic (Middle Eastern)
- •56.9.5 Aging
- •56.9.6 Revision Rhinoplasty
- •56.10 Discussion
- •56.11 Conclusions
- •References
- •57: Lip Enhancement: Personal Technique
- •57.1 Introduction
- •57.2 Anatomical Basics of the Human Lip
- •57.3 Injectable Materials
- •57.4 Technique
- •57.5 Postoperative Instructions
- •57.6 Complications
- •57.7 Discussion
- •References
- •58.1 Introduction
- •58.2 Advantages
- •58.3 Mechanism of Action
- •58.4 The Tumescent Technique
- •58.5 Indications
- •58.6 Contraindications
- •58.7 Technique
- •58.8 Complications
- •58.9 Special Considerations
- •58.9.1 Submandibular Gland Exposure
- •58.9.2 Platysmal Band Exposure
- •58.9.3 Thyroid Thickness or Band
- •58.9.4 Receding Chin
- •References
- •59: Neck Lifting Variations
- •59.1 Introduction
- •59.2 Pathophysiology of the Aging Neck
- •59.2.1 Aging Skin
- •59.2.2 Aging Soft Tissue
- •59.2.3 Aging Facial Skeleton
- •59.3 Other Factors
- •59.4 Evaluation of the Aging Neck
- •59.4.2 Physical Findings
- •59.5 Jowl/Mandibular Evaluation
- •59.6 Submental/Neck Evaluation
- •59.7 Surgical Technique Selection
- •59.7.1 Nonsurgical Intervention
- •59.7.2 Botulinum Toxin A
- •59.7.3 Skin Tightening Procedures
- •59.7.4 Intradermal Fillers
- •59.7.5 Laser Resurfacing
- •59.8 Surgical Treatment
- •59.8.1 Liposculpting
- •59.8.2 Platysmaplasty
- •59.8.3 Rhytidoplasty
- •59.9 Special Neck Lifting
- •59.9.1 Vertical Neck Lift
- •59.9.2 Horizontal Neck Lift
- •59.10 Clinical Pearls and Pitfalls
- •References
- •60.1 Introduction
- •60.2 Technique
- •60.3 Instructions
- •60.3.1 Day of Treatment
- •60.3.2 Second Day: Micropore Tape Mask Removal and Application of Subgalatic Mask
- •60.3.3 Eighth Day: Bismuth Subgalatic Mask Removal
- •60.4 Patient Instructions
- •60.4.1 Shopping List
- •60.4.2 Night Before Procedure
- •60.4.3 The Procedure (Day 1)
- •60.4.6 Days Four (4) to Seven (7)
- •60.4.7 Mask Removal on Day Eight (8)
- •60.5 Remember
- •60.6 Complications
- •60.7 Discussion
- •60.8 Conclusions
- •61.1 Applications of Permanent Cosmetics
- •61.2 Preprocedure Preparation
- •61.3 Pigment Blends
- •61.4 Eyebrows
- •61.5 Lips
- •61.6 Postprocedure Considerations
- •61.6.1 Longevity
- •61.6.2 Risks
- •61.7 Conclusions
- •Recommended Reading
- •62.1 Introduction
- •62.4 Mechanism of Action/Histology
- •62.5 Technique
- •62.6 Longevity
- •62.7 Complications
- •62.8 Conclusions
- •References
- •63.2 Prevalence
- •63.3 Clinical Features
- •63.3.1 Morphological Changes
- •63.3.2 Metabolic Changes
- •63.3.3 Pathogenesis
- •63.3.4 Protease Inhibitors
- •63.4 HIV Infection
- •63.5 Nutritional Status, Age, and Adiposity
- •63.6 Female Sex
- •63.7 Cytokines
- •63.8 Management
- •63.8.1 Nonsurgical Treatment of HIV Facial Lipoatrophy
- •63.9 Autologous Fat Transfer
- •63.9.1 History of Autologous Fat Transfer
- •63.10 Theories of Fat Graft Survival
- •63.11 Histological Evaluation of Transplanted Fat
- •63.12 Technique
- •63.13 Surgical Technique
- •63.13.1 Anaesthesia of the Donor Site
- •63.13.2 Choice of Donor Site
- •63.13.3 Harvesting Method
- •63.15 Placement
- •63.16 Post-operative Care
- •63.17 Complications
- •63.18 Discussion
- •63.19 Conclusions
- •References
- •64.1 Introduction
- •64.2 Comparative Studies
- •References
- •65.1 Introduction
- •65.2.1 Duty
- •65.2.2 Breach of Duty (Negligence)
- •65.2.3 Causation
- •65.2.4 Damages
- •65.3 Avoiding Lawsuits
- •65.4 What to Do When a Lawsuit Is Threatened or Filed
- •Index
7 Personal Method of Anesthesia in the Office |
79 |
Table 7.3 BIS levels and levels of sedation/anesthesia
BIS
100–85 |
Awake: capable of memory |
|
processing and explicit recall |
85–75 |
Minimal sedation (anxiolysis) |
75–70 |
Moderate (“conscious”) sedation |
70–60 |
Deep sedation |
60–40 |
General anesthesia |
<40 |
Over anesthetized |
of surgical stimulation, but during surgery the antinociceptive influence leads to a decrease in BIS. Ketamine causes a dose-dependent activation of the EEG with subsequent increase in BIS values.
The concept of “entropy” has been applied to the EEG, as a way of quantifying its degree of order [17, 18]. One particular entropy concept, Shannon entropy, has been shown to correlate with anesthetic drug effect [19]. In essence, Shannon entropy measures the predictability of future amplitude values of the EEG based on amplitude values previously observed in the signal. Spectral entropy applies this Shannon entropy concept. Presently, the only commercially available entropy module (M-Entropy, Datex-Ohmeda, Finland) looks at two spectral entropy indicators: “state entropy” (SE) covering the dominant EEG frequency (0.8–32 Hz) and “response entropy” (RE) over the complete range of frequencies (0.8–47 Hz). The latter range includes both EEG and EMG components. The SE has a range (0–91) and RE (0–100) with lower numbers denoting a deeper level of anesthesia.
Vanluchene ALG et al. [20] compared BIS and spectral entropy in patients receiving a propofol infusion with or without remifentanil. BIS and spectral entropy accurately detected loss of consciousness to verbal command and decreased proportionately when remifentanil was used.
It is important to understand that BIS displays considerable variability within study populations, so making it difficult to identify sensitive and specific threshold values. Importantly, no BIS value predicts an individual threshold. Level of consciousness monitors is no substitute for vigilance, their true merit lies in their ability to enable the anesthetist to tailor the anesthetic to the individual.
7.5 Agents Used in Sedation
7.5.1 Propofol
A phenolic derivative (2,6 diisopropylphenol) is highly lipid soluble, a weak organic acid (pKa = 11), and almost entirely unionized at pH = 7.4. It is close to being the ideal agent for sedation and possesses a very favorable pharmacokinetic profile, with fast induction and ability to rapidly change sedation level together with a prompt recovery. Propofol exerts its effects via the E subunit of the GABAA receptor as well as releasing the neuroinhibitory transmitter, glycine. Sedation and amnesia are dose related though the amnesic effect is not as powerful as midazolam [9, 21]. Anxiolysis is not dose related. Pain on injection can occur, especially if a small calibre vein is used. Propofol is a poor analgesic [6] but has valuable antiemetic properties [21]. Doses in excess of 200 mg/h can induce hypotension and bradycardia. In the office setting, this can be offset with the use of low dose ketamine [22].
7.5.2 Benzodiazepines
Midazolam is the favored benzodiazepine (BDZ). Midazolam is a clear solution with a pH = 3.5 but is unique in that its structure depends on the surrounding pH. With increasing pH, the diazepine ring closes becoming unionized and lipid soluble [23]. Midazolam has the highest clearance (6–10 ml/kg/min) of all the commonly used BDZ and has a reasonable onset/offset profile but considerably slower than propofol. Like other benzodiazepines, midazolam is an agonist at the BZD receptor site (interface between D,J subunits on the GABAA receptor) and is a good sedative with excellent amnesic properties but no analgesic action [24]. Flumzenil is a specific antagonist, thereby providing a layer of safety, though it clears faster than midazolam and rebound sedation can occur.
7.5.3 Clonidine and Dexmedetomidine
These drugs are D2 adrenoceptor agonists, possessing potent anxiolytic and sedative actions. These agents stimulate D2 adrenoceptors in the lateral reticular
80 |
S.J. Gray |
nucleus, so reducing central sympathetic outflow and in the spinal cord promote opioid release thereby modulating the descending noradrenergic pathway involved in spinal nociceptive processing. Clonidine has a relatively slow onset/offset profile with a distribution halflife of 1.2 h and an elimination half-life of 14.6 h. So, if used orally, the dose must be given 30–60 min before surgery. Clonidine at high doses (5 Pg/kg orally or 4 Pg/ kg intravenous) has analgesic properties, does not impair respiration or induce nausea/vomiting [25]. Cardiovascular instability is more common in the elderly.
Dexmedetomidine is up to eight times more potent than clonidine, has a faster onset/offset profile (elimination half-life 2 h), making it more readily titratable. It is much more expensive with concerns being raised regarding hemodynamic instability and associated nausea/vomiting [26].
Both agents impair thermoregulatory mechanisms and can decrease postoperative shivering.
7.5.4 Ketamine
Developed in the 1960s, ketamine, a phencyclidine derivative, is a racemic mixture of S(+) enantiomer, which is two to three times more potent than the R(−) enantiomer. The (S+) enantiomer causes less dysphoria and is the preferred preparation in Europe. S(+) also has a role moderating opioid-induced hyperalgesia. Ketamine is water soluble forming an acidic solution with pH = 3.5–5.5 and is known to act by inhibiting the NMDA receptor in a noncompetitive manner, producing dissociative anesthesia. EEG analysis depicts dissociation between thalamocortical and limbic systems. Outpatient anesthesia has provided the foundation for its resurgence with low dose (0.5–1.0 mg/kg) regimes providing weak sedation but excellent analgesia. Additionally, ketamine’s stimulation of the sympathetic nervous system counters the hypotension and respiratory depression associated with propofol [22]. Dose-related nausea/vomiting can be troublesome. Sedative doses of propofol can allay the disturbing dysphorias/hallucinations.
7.5.5 Opioids
Despite techniques employing propofol, ketamine, and clonidine, the author’s practice is not devoid of opioids.
From an office-based perspective, remifentanil has provided substantial interest. Remifentanil is a very potent, pure P agonist with a time-independent context half time (duration of action determined by metabolism not distribution). The elimination halflife is 3–10 min, being metabolized by nonspecific plasma and tissue esterases. This contrasts with alfentanil, sufentanil, and fentanyl all having longer context sensitive half times. Notwithstanding its intense analgesic action, remifentanil is a poor anxiolytic and amnesic [27]. Hemodynamic instability does not seem to be a problem and probably due to its ultrashort duration of action, nausea/vomiting is less common. Perhaps its major drawback in the office setting is the profound respiratory depression this agent induces [28].
7.5.6 Acetaminophen
A para-aminophenol derivative, acetaminophen has no effect on cyclooxygenase in vitro and is a capable antipyretic and analgesic in mild to moderate pain. In Europe, the use of the intravenous preparation is ubiquitous. In an office-based practice, acetaminophen has secured a role through its opioid-sparing effect. Overdose can be fatal as it leads to exhaustion of hepatic glutathione reserves and possible liver failure.
7.5.7Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
NSAIDs inhibit the enzyme cyclooxygenase (COX). Cyclooxygenase exists as two isoenzymes. COX-1 (the constitutive form) mediates the synthesis of thromboxane, produces prostaglandins controlling renal blood flow, and is instrumental in forming the protective gastric mucosal barrier. Platelets generate thromboxane on exposure to collagen, adenosine, and adrenaline thereby encouraging hemostasis through vasoconstriction and platelet aggregation. COX-2 (the inducible form) is produced where there is tissue damage. It amplifies the inflammatory response yet paradoxically generates prostcyclin (PGI2) in the vascular endothelium. Prostacyclin causes vasodilatation and inhibits platelet aggregation.
